| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Adrian W Quartel is Chief Medical Officer at ZVRA. Adrian W Quartel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $100K at current prices.
The ZVRA filings lean toward selling, a net 4,533 shares.
Adrian W Quartel has 3 Form 4 filings on record from January 2025 to July 2026, across 2 companies: Chief Medical Officer at Spruce Biosciences (SPRB), 2026; Chief Medical Officer at Zevra Therapeutics (ZVRA), 2025–2026.
The 7 reported transactions were 5 option or other derivative awards, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $40K.
The only open-market sale was 4,533 shares of ZVRA at an average $8.83 on January 30, 2026, about $40K.